MCID: RHN004
MIFTS: 57

Rhinitis

Categories: Bone diseases, Respiratory diseases, Smell/Taste diseases

Aliases & Classifications for Rhinitis

MalaCards integrated aliases for Rhinitis:

Name: Rhinitis 12 29 54 43 15 17 71
Runny Nose 12

Classifications:



External Ids:

Disease Ontology 12 DOID:4483
MeSH 43 D012220
NCIt 49 C34986
SNOMED-CT 67 70076002
UMLS 71 C0035455

Summaries for Rhinitis

Disease Ontology : 12 A upper respiratory infectious disease which involves irritation and inflammation of the mucous membrane of the nose due to viruses, bacteria or irritants. The inflammation results in generation of excessive amounts of mucus leading to runny nose, as well as nasal congestion and post-nasal drip.

MalaCards based summary : Rhinitis, also known as runny nose, is related to chronic rhinitis and ige responsiveness, atopic, and has symptoms including rhinorrhea, sneezing and sinus congestion. An important gene associated with Rhinitis is IL13 (Interleukin 13), and among its related pathways/superpathways are Innate Immune System and PEDF Induced Signaling. The drugs Zolmitriptan and Epinephrine have been mentioned in the context of this disorder. Affiliated tissues include testes, skin and t cells, and related phenotypes are growth/size/body region and hematopoietic system

Wikipedia : 74 Rhinitis, also known as coryza, is irritation and inflammation of the mucous membrane inside the nose.... more...

Related Diseases for Rhinitis

Diseases in the Rhinitis family:

Chronic Rhinitis

Diseases related to Rhinitis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 613)
# Related Disease Score Top Affiliating Genes
1 chronic rhinitis 34.9 RNASE3 IL5 IL4 IL13 HRH1 EPX
2 ige responsiveness, atopic 33.9 RNASE3 IL5 IL4R IL4 IL13 IGHE
3 allergic rhinitis 33.7 VCAM1 RNASE3 NR3C1 NGF KNG1 IL5
4 pollen allergy 33.3 RNASE3 IL5 IL4R IL13 ICAM1 EPX
5 churg-strauss syndrome 32.9 RNASE3 IL5 CYSLTR1 CXCL8 CCL11
6 respiratory syncytial virus infectious disease 32.8 IL5 IL13 CCL5
7 allergic conjunctivitis 32.7 RNASE3 IL5 IL4 IL13 IGHE ICAM1
8 common cold 32.6 RNASE3 IL5 IL4 IL13 ICAM1 CYSLTR1
9 giant papillary conjunctivitis 32.6 RNASE3 IL4 CXCL8 CCL11
10 allergic asthma 32.3 VCAM1 RNASE3 IL5 IL4R IL4 IL13
11 cytokine deficiency 31.9 IL5 IL13
12 urticaria 31.9 RNASE3 IL5 IL4 IL13 IGHE HRH1
13 dermatitis 31.8 RNASE3 IL5 IL4 IL13 IGHE HRH1
14 hypereosinophilic syndrome 31.7 RNASE3 IL5 IL4 IL13 IGHE EPX
15 otitis media 31.6 RNASE3 IL5 IL4 IGHE ICAM1 CXCL8
16 dermatitis, atopic 31.6 VCAM1 RNASE3 NGF KNG1 IL5 IL4R
17 conjunctivitis 31.5 RNASE3 IL5 IL4 IL13 IGHE ICAM1
18 sleep apnea 31.5 VCAM1 ICAM1 CXCL8
19 respiratory allergy 31.4 RNASE3 IL5 IL4R IL4 IL13 IGHE
20 gastroesophageal reflux 31.3 IL5 IL4 CXCL8 CCL11
21 food allergy 31.3 RNASE3 IL5 IL4R IL4 IL13 IGHE
22 bronchitis 31.2 RNASE3 IL5 IL4 IL13 IGHE CXCL8
23 contact dermatitis 31.1 IL5 IL4 ICAM1 CXCL8
24 aspergillosis 31.1 IL5 IL4 EPX CXCL8 CCL5
25 leprosy 3 31.0 IL5 IL4 CXCL8
26 drug allergy 31.0 IL5 IL4R IGHE CYP3A4
27 proteasome-associated autoinflammatory syndrome 1 31.0 VCAM1 RNASE3 IL5 IL4 IL13 ICAM1
28 angioedema 30.9 KNG1 IL5 IGHE HRH1
29 autoimmune disease 30.9 VCAM1 IL5 IL4 IL13 CXCL8 CCL5
30 egg allergy 30.9 IL5 IL4 IGHE
31 graves' disease 30.8 IL4 IL13 ICAM1 CCL5
32 lung disease 30.8 RNASE3 IL5 IL4 IL13 ICAM1 CXCL8
33 milk allergy 30.8 RNASE3 IL5 IL4 IL13 IGHE
34 fibromyalgia 30.8 POMC NGF CXCL8
35 allergic bronchopulmonary aspergillosis 30.8 IL5 IL4 IGHE EPX
36 pulmonary disease, chronic obstructive 30.8 RNASE3 NR3C1 IL5 IL4 IL13 CXCL8
37 anxiety 30.8 POMC NR3C1 NGF CYP3A4
38 latex allergy 30.8 RNASE3 IL5 IL4 IL13 IGHE
39 irritable bowel syndrome 30.7 POMC NGF CXCL8
40 intrinsic asthma 30.7 RNASE3 IL5 IL4 IL13 IGHE CCL11
41 skin disease 30.7 RNASE3 IL5 IL4 IL13 ICAM1 HRH1
42 cough variant asthma 30.7 RNASE3 NGF IL5 IL4 IGHE
43 pneumonia 30.7 IL5 IL4 IL13 ICAM1 CXCL8 CCL5
44 esophagitis, eosinophilic, 1 30.7 RNASE3 IL5 IL4 IL13 EPX CCL11
45 peanut allergy 30.7 IL5 IL4 IL13 IGHE
46 allergic contact dermatitis 30.7 IL5 IL4 ICAM1 CXCL8
47 migraine with or without aura 1 30.7 POMC NGF KNG1 CYP3A4
48 gingivitis 30.6 IL4 ICAM1 CXCL8 CCL5
49 esophagitis 30.6 IL5 IL4 IL13 CXCL8 CCL5 CCL11
50 osteomyelitis 30.6 IL4 CXCL8 CCL5

Graphical network of the top 20 diseases related to Rhinitis:



Diseases related to Rhinitis

Symptoms & Phenotypes for Rhinitis

UMLS symptoms related to Rhinitis:


rhinorrhea, sneezing, sinus congestion, nasal congestion (finding), nasal irritation, posterior rhinorrhea

MGI Mouse Phenotypes related to Rhinitis:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 growth/size/body region MP:0005378 10.03 FOXJ1 HRH1 ICAM1 IL13 IL4 IL4R
2 hematopoietic system MP:0005397 9.93 CCL11 CCL5 EPX HRH1 ICAM1 IL13
3 immune system MP:0005387 9.77 CCL11 CCL5 CYSLTR1 EPX HRH1 ICAM1
4 respiratory system MP:0005388 9.23 CCL11 CYSLTR1 FOXJ1 IL13 IL4 IL4R

Drugs & Therapeutics for Rhinitis

Drugs for Rhinitis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 390)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Zolmitriptan Approved, Investigational Phase 4 139264-17-8 441240 60857
2
Epinephrine Approved, Vet_approved Phase 4 51-43-4 5816
3
Racepinephrine Approved Phase 4 329-65-7 838
4
Lansoprazole Approved, Investigational Phase 4 103577-45-3 3883
5
Dexlansoprazole Approved, Investigational Phase 4 138530-94-6, 103577-45-3 9578005
6
Diphenhydramine Approved, Investigational Phase 4 147-24-0, 58-73-1 3100
7
Promethazine Approved, Investigational Phase 4 60-87-7 4927
8
Cetirizine Approved Phase 4 83881-51-0 2678
9
Loratadine Approved, Investigational Phase 4 79794-75-5 3957
10
Desloratadine Approved, Investigational Phase 4 100643-71-8 124087
11
Fexofenadine Approved, Investigational Phase 4 83799-24-0 3348
12
Levocetirizine Approved Phase 4 130018-77-8 1549000
13
Montelukast Approved Phase 4 158966-92-8 5281040
14
Triamcinolone Approved, Vet_approved Phase 4 124-94-7 31307
15
Adenosine Approved, Investigational Phase 4 58-61-7 60961
16
Resveratrol Approved, Experimental, Investigational Phase 4 501-36-0 445154
17
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 6741
18
Prednisolone Approved, Vet_approved Phase 4 50-24-8 5755
19
Methylprednisolone hemisuccinate Approved Phase 4 2921-57-5
20
Prednisolone phosphate Approved, Vet_approved Phase 4 302-25-0
21 Prednisolone acetate Approved, Vet_approved Phase 4 52-21-1
22
Betamethasone Approved, Vet_approved Phase 4 378-44-9 9782
23
Ethanol Approved Phase 4 64-17-5 702
24
Doxazosin Approved Phase 4 74191-85-8 3157
25
Theophylline Approved Phase 4 58-55-9 2153
26
Xylometazoline Approved, Investigational Phase 4 526-36-3 5709
27
Prazosin Approved Phase 4 19216-56-9 4893
28
Ebastine Approved, Investigational Phase 4 90729-43-4 3191
29
Budesonide Approved Phase 4 51333-22-3 63006 5281004
30
Sodium citrate Approved, Investigational Phase 4 68-04-2
31
Sotalol Approved Phase 4 959-24-0, 3930-20-9 5253
32
mometasone furoate Approved, Investigational, Vet_approved Phase 4 83919-23-7
33
Citric acid Approved, Nutraceutical, Vet_approved Phase 4 77-92-9 311
34
Prednisolone hemisuccinate Experimental Phase 4 2920-86-7
35
Tranilast Investigational Phase 4 53902-12-8 93543
36 Serotonin 5-HT1 Receptor Agonists Phase 4
37 Serotonin Receptor Agonists Phase 4
38 Oxazolidinones Phase 4
39 Proton Pump Inhibitors Phase 4
40 Adrenergic beta-Agonists Phase 4
41 Epinephryl borate Phase 4
42 Purple Butterbur Phase 4
43 Anesthetics, Local Phase 4
44 Antiemetics Phase 4
45 Hypnotics and Sedatives Phase 4
46 Central Nervous System Depressants Phase 4
47 Adrenergic alpha-Antagonists Phase 4
48 Cholinergic Antagonists Phase 4
49 Free Radical Scavengers Phase 4
50
Beclomethasone Phase 4 4419-39-0 20469

Interventional clinical trials:

(show top 50) (show all 1247)
# Name Status NCT ID Phase Drugs
1 Efficacy and Safety of Zolmitriptan by Sublingual Administration in the Treatment of Cluster Headache: A Multi-center Randomized Cross-controlled Trial Unknown status NCT03377257 Phase 4 zolmitriptan by sublingual administration;zolmitriptan by oral
2 Comparison of the Effect of Montelukast and Cetirizine on Allergic Inflammation Measured by Exhaled Nitric Oxide Concentration in Children With Seasonal Allergic Rhinitis Unknown status NCT00488176 Phase 4 montelukast;cetirizine;montelukast and cetirizine;placebo
3 Elaboration of Patient-friendly Treatment Strategy With Capsaicin Nasal Spray in Patients With Idiopathic Rhinitis Unknown status NCT02288156 Phase 4 Capsaicin;placebo
4 Immunological Mechanisms of Oralair® (5 Grass Mix Sublingual Allergen Immunotherapy Tablet) in Patients With Seasonal Allergic Rhinitis Unknown status NCT02014623 Phase 4 Control
5 Assessment of Effectiveness and Safety of Annual Sublingual Immunotherapy in Children With Bronchial Asthma and/or Allergic Rhinitis Allergic to House Dust Mites Unknown status NCT01052610 Phase 4 sublingual house dust mites allergen extract;placebo in sublingual applicator
6 A Randomized, Parallel, Double-blind, Multi-center, Comparative Study to Exploratively Evaluate the Efficacy and Safety of Cosalin® Monotherapy vs. Cosalin® and Xarlin® Combination Therapy in Patients With Allergic Rhinitis Unknown status NCT01062139 Phase 4 Xarlin (Levocetirizine);Cosalin (Petasites hybridus CO2 extract)
7 The Evaluation of Singulair for the Treatment of Non-Allergic Rhinitis Eosinophil Syndrome (NARES) Unknown status NCT00406094 Phase 4 montelukast;placebo
8 SINOL + MucoAd™ (SMAN) Evaluation Trial: A Double-Blind, Cross-Over Comparison of SINOL and SMAN in Subjects With Congestion Due to Allergic Rhinitis Unknown status NCT00825656 Phase 4 Sinol or Sinol-M nasal spray
9 AZE/FLU Nasal Spray on Symptom Control, Nasal Mediators and Nasal Hyperresponsiveness in Allergic Rhinitis (AR) Unknown status NCT02238353 Phase 4 azelastine + fluticasone;Placebo
10 The Relationship Between Gastroesophageal Reflux and Pediatric Rhinitis: Significance of Pale/Blue Colored Turbinate. A Randomized Controlled Trial Unknown status NCT02278081 Phase 4 lansoprazole;placebo
11 Evaluating Factors Involved in Dymista's Superior Clinical Efficacy to Fluticasone Propionate in the Treatment of Seasonal Allergic Rhinitis Unknown status NCT02402465 Phase 4 Placebo;Fluticasone propionate;Fluticasone/Azelastine nasal spray
12 Real Life Proof-of-Concept Study to Assess the Effect of Methylcellulose as add-on "Seal" to the In-season Pharmacologic Rescue Treatment in Subjects With Allergic Rhinitis Unknown status NCT02557269 Phase 4 Xylometazoline - intranasal application;Azelastine - intranasal application;Mometasone furoate - intranasal application;Hydroxyl-propyl-methyl cellulose powder - intranasal application;Bilastine 20 mg;Prednisolone 5 mg
13 Comparing Treatment Efficacy With High and Medium Dose of Fluticasone in Combination With Salmeterol in COPD Patients Unknown status NCT01657487 Phase 4 Fluticasone/Salmeterol high dose
14 Changes in Exhaled Breath Temperature During the Pollen Season in Subjects With Allergic Rhinoconjunctivitis Sensitized to Grasses and Effect of Sublingual Immunotherapy Unknown status NCT01785394 Phase 4 5 grass allergen extract
15 Bronchiolitis All-study, SE-Norway What is the Optimal Inhalation Treatment for Children 0-12 Months With Acute Bronchiolitis? Unknown status NCT00817466 Phase 4 Racemic adrenaline;Isotonic saline
16 Efficacy of Systemic Glucocorticoid in the Treatment of Wheezing in Children Unknown status NCT00494624 Phase 4 prednisolone
17 Randomized, Double Blind, Parallel Group, Placebo Controlled, Multi-Center Study of the Efficacy and Safety of Zyrtec® (Cetirizine HCl) Syrup vs. Claritin® (Loratadine) Syrup vs. Placebo in Treatment of Children With Seasonal Allergic Rhinitis (SAR) Completed NCT02932774 Phase 4 Cetirizine;Loratadine
18 A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Effect of Long-Term Treatment With Rhinocort Aqua (Budesonide) Nasal Spray in Children With Perennial Allergic Rhinitis. Completed NCT00641212 Phase 4 Budesonide;Placebo
19 A Comparison of Fluticasone Furoate Nasal Spray Versus Oral Fexofenadine in the Treatment of Seasonal Allergic Rhinitis Completed NCT00502775 Phase 4 fluticasone furoate, fexofenadine
20 Levocetirizine Effect on Nasal Nitric Oxide and Nasal Eosinophils in Subjects With Perennial Allergic Rhinitis Completed NCT00894231 Phase 4 levocetirizine (Xyzal);placebo
21 Safety and Efficacy of Olopatadine 0.6% and Azelastine 137 Mcg in Vasomotor Rhinitis Completed NCT00979615 Phase 4 Olopatadine HCL (Patanase) Nasal Spray, 0.6%;Azelastine HCl (Astelin) Nasal Spray, 137 mcg
22 Allergic Rhinitis Changes the Sinus Microbiome Completed NCT01852513 Phase 4 QNASL;Placebo nasal spray
23 Evaluation of Efficacy, Using the Number of Comfortable Days and the Safety of Levocetirizine Dihydrochloride, Administered Once Daily in the Evening for 30 Days, to Subjects Suffering From Perennial Allergic Rhinitis to House Dust Mites Completed NCT00521131 Phase 4 Levocetirizine dihydrochloride
24 A Comparison of Fluticasone Furoate Nasal Spray Versus Oral Fexofenadine in the Treatment of Seasonal Allergic Rhinitis Completed NCT00435461 Phase 4 Fluticasone furoate and fexofenadine
25 Evaluation of the Sensory Attributes of Olopatadine 0.6% and Azelastine 137mcg Nasal Sprays in Patients w/Allergic Rhinitis Completed NCT00772304 Phase 4 Olopatadine 0.6% / Azelastine 137 mcg
26 The Addition of Vitamin D to Fluticasone Propionate in the Management of Seasonal Allergic Rhinitis Completed NCT01103934 Phase 4 Vitamin D3;Placebo;Fluticasone Propionate
27 A Double-masked, Randomized, Parallel Group, Comparison of Olopatadine 0.6% and Fluticasone Proprionate 50mcg Nasal Sprays in a Two Week Seasonal Allergic Rhinitis Trial Completed NCT00691665 Phase 4 Olopatadine HCL Nasal Spray, 0.6%;Fluticasone Propionate Nasal Spray, 50 mcg
28 A Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel-group Study Evaluating the Efficacy and Impact on Health-related Quality of Life of Levocetirizine 5 mg Once Daily Given for 2 Weeks in Subjects 18 yr of Age and Older With Seasonal Allergic Rhinitis Completed NCT00621959 Phase 4 levocetirizine dihydrochloride;placebo
29 Efficacy of Mite Allergen Vaccine Among Thai Patients With Allergic Rhinitis Completed NCT01115595 Phase 4
30 A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter, Two-Year Study to Evaluate the Ocular Safety of Once-Daily, Fluticasone Furoate Nasal Spray 110mcg in Adults and Adolescents 12 Years of Age and Older With Perennial Allergic Rhinitis Completed NCT00682643 Phase 4 fluticasone furoate nasal spray;vehicle placebo nasal spray
31 A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy and Safety of Once-Daily Intranasal Administration of Fluticasone Furoate Nasal Spray 110mcg in Adult and Adolescent Subjects 12 Years of Age and Older With Perennial Allergic Rhinitis (PAR) Completed NCT00609674 Phase 4 Fluticasone furoate nasal spray;Placebo
32 Trial to Compare the Efficacy and Safety of Levocetirizine 5 mg od and Fexofenadine 120 mg od in Reducing Symptoms of Seasonal Allergic Rhinitis in Grass Pollen Sensitized Adults Completed NCT00542607 Phase 4 levocetirizine dihydrochloride
33 A Monitored Release Study On The Efficacy And Safety of Fexofenadine (Telfast®) 30mg Pediatric Tablets On Filipino Children Aged 6 To 11 for The Relief of Perennial And Intermittent Allergic Rhinitis. Completed NCT00741897 Phase 4 Fexofenadine
34 Efficacy and Safety of Nasonex vs. Placebo in Subjects With SAR and Concomitant Asthma Completed NCT00070707 Phase 4 Mometasone;Placebo;Albuterol/Salbutamol
35 A Pilot, Open, Monocenter, Randomized Two Parallel Groups, Clinical Efficacy Trial: Comparison Continuous Versus on Demand Regimen of Treatment With Levocetirizine 5 mg Oral Tablets, Once a Day, in Adults Suffering From Persistent Allergic Rhinitis (PER) Over 6 Months Completed NCT00160680 Phase 4 Levocetirizine
36 A Multicentre, Double-blind, Parallel, Randomized, Placebo-controlled Study : Evaluation of the Efficacy and Safety of Levocetirizine 5 mg and Desloratadine 5 mg Administered Orally as Capsules Once Daily, in the Morning, Over 2 Weeks in Patients Suffering From Allergic Rhinitis (AR) Completed NCT00160589 Phase 4 Levocetirizine
37 A Monocenter, Double-blind, Randomized Trial, With Two Parallel Groups Comparing the Clinical Efficacy of Levocetirizine 5 mg Capsules and Desloratadine 5 mg Capsules Taken Once a Day Over 3 Weeks of Treatment in Adult Subjects Suffering From Seasonal Allergic Rhinitis (SAR) Due to Grass Pollen Completed NCT00160537 Phase 4 Levocetirizine
38 Evaluation of NasoNeb™ Delivery of an Intranasal Steroid in the Treatment of Perennial Allergic Rhinitis Completed NCT01270256 Phase 4 Budesonide;Placebo
39 Effects of Hypertonic Saline Solution (NACL 3%+NAHCO3) on Nasal Inflammation in Children With Allergic Rhinitis. RinASol- Pilot Study (Allergic Rhinitis Solution) Completed NCT02729012 Phase 4 hypertonic saline solution (NACL 3%+NAHCO3)
40 Proteomic Profiling for Influenza Vaccination Completed NCT00133588 Phase 4
41 Prospective, Randomized, Controlled, Observer-Blind Trial to Measure the Efficacy, Safety and Immunogenicity of Trivalent Inactivated Influenza Vaccine and the Safety and Immunogenicity of Quadrivalent Meningococcal Polysaccharide Diphtheria Conjugate Vaccine in Pregnant Malian Women and Their Infants up to 6 Months of Age Completed NCT01430689 Phase 4
42 A Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel-group Study Evaluating the Efficacy and Impact on Health-related Quality of Life of Levocetirizine 5 mg Once Daily Given for 2 Weeks in Subjects 18 yr of Age and Older With Seasonal Allergic Rhinitis Completed NCT00653224 Phase 4 levocetirizine dihydrochloride;placebo
43 Montelukast as a Controller of Atopic Syndrome Completed NCT00559546 Phase 4 montelukast
44 Korean Study of "Real-World" Montelukast Use in Mild Asthmatic Children With Concomitant Allergic Rhinitis Completed NCT00442559 Phase 4 montelukast sodium;inhaled corticosteroid
45 The Efficacy and Safety of Hyeonggaeyeongyo-tang for Chronic Rhinitis According to Pattern Identification in Korean Medicine Completed NCT02477293 Phase 4 Hyeonggaeyeongyo-tang
46 Molecular and Cellular Mechanism in Rhinitis Allergic Patients Treated With GRAZAX® Completed NCT02437786 Phase 4 GRAZAX
47 Quality of Life in Asthma and Rhinitis Allergic With Singulair Completed NCT00380705 Phase 4 MK0476, Singulair, montelukast sodium / Duration of Treatment: 8 Weeks
48 A Multi-center, Open, Randomized, Three-arm, Parallel-group, Phase IV Study to Compare the Efficacy of Ciclesonide Nasal Spray and Levocetirizine, Alone and in Combination for the Patient With Allergic Rhinitis Completed NCT01430260 Phase 4 Ciclesonide;Levocetirizine;Ciclesonide & Levocetirizine
49 A Multi-center, Open-label, Non-comparative Study of the Relief of Nasal Symptoms and Tolerability in Subjects With Seasonal Allergic Rhinitis (SAR) Treated With Aerius. Completed NCT00805584 Phase 4 desloratadine
50 Intranasal Steroids Prevent Antigen-Induced Hyperresponsiveness of the Nasal Ocular Response Completed NCT00473915 Phase 4 fluticasone furoate

Search NIH Clinical Center for Rhinitis

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Ephedra vulgaris preparation
Ephedrine
Ephedrine hydrochloride
Ephedrine sulfate
EPHEDRINE TANNATE
Hyoscyamine
Hyoscyamine hydrobromide
Hyoscyamine Sulfate
Naphazoline
Naphazoline Hydrochloride
Oxymetazoline
Oxymetazoline hydrochloride
Phenylpropanolamine

Cochrane evidence based reviews: rhinitis

Genetic Tests for Rhinitis

Genetic tests related to Rhinitis:

# Genetic test Affiliating Genes
1 Rhinitis 29

Anatomical Context for Rhinitis

MalaCards organs/tissues related to Rhinitis:

40
Testes, Skin, T Cells, Lung, Eye, Bone, Pituitary

Publications for Rhinitis

Articles related to Rhinitis:

(show top 50) (show all 26464)
# Title Authors PMID Year
1
The role of mast cell-derived secreted phospholipases A2 in respiratory allergy. 54 61
20219624 2010
2
[Evaluating total serum IgE levels and peripheral eosinophil count in asthma and rhinitis]. 54 61
20502102 2010
3
Reduced helminth burden increases allergen skin sensitization but not clinical allergy: a randomized, double-blind, placebo-controlled trial in Vietnam. 54 61
19758373 2010
4
Nasal inflammatory mediators and specific IgE production after nasal challenge with grass pollen in local allergic rhinitis. 54 61
19796796 2009
5
Randomized controlled trial of oral antifungal treatment for severe asthma with fungal sensitization: The Fungal Asthma Sensitization Trial (FAST) study. 54 61
18948425 2009
6
Association of single nucleotide polymorphisms in the eosinophil peroxidase gene with allergic rhinitis in the Czech population. 54 61
19439985 2009
7
Advances in upper airway diseases and allergen immunotherapy in 2007. 54 61
18694591 2008
8
Rhinitis and onset of asthma: a longitudinal population-based study. 54 61
18805333 2008
9
Change in prevalence of atopic dermatitis between 1986 and 2001 among children. 54 61
18702887 2008
10
Paediatric allergy diagnosis in primary care is improved by in vitro allergen-specific IgE testing. 54 61
18312533 2008
11
Recent progress in allergen immunotherapy. 54 61
18319521 2008
12
Patterns of GATA3 and IL13 gene polymorphisms associated with childhood rhinitis and atopy in a birth cohort. 54 61
18037162 2008
13
Quantification of atopy and the probability of rhinitis in preschool children: a population-based birth cohort study. 54 61
17822449 2007
14
Anti-IgE in allergic asthma and rhinitis: an update. 54 61
17961096 2007
15
A recombinant humanized anti-IgE monoclonal antibody (omalizumab) in the therapy of moderate-to-severe allergic asthma. 54 61
19075985 2007
16
[Clinical observation on treatment of children's mild continuous asthma by Fangchuan Mixture combined with flixotide]. 54 61
18173144 2007
17
A phase 3 randomized controlled trial of the efficacy and safety of atrasentan in men with metastatic hormone-refractory prostate cancer. 54 61
17886253 2007
18
Systemic and local eosinophil inflammation during the birch pollen season in allergic patients with predominant rhinitis or asthma. 54 61
17967188 2007
19
Allergic asthma and rhinitis caused by household rabbit exposure: identification of serum-specific IgE and its allergens. 54 61
17982229 2007
20
Polymorphisms of histamine-metabolizing enzymes and clinical manifestations of asthma and allergic rhinitis. 54 61
17651147 2007
21
Mediators and cytokines in allergic and viral-triggered rhinitis. 54 61
17883911 2007
22
Cysteinyl-leukotriene levels in sputum differentiate asthma from rhinitis patients with or without bronchial hyperresponsiveness. 54 61
17581201 2007
23
Up-regulation of protease-activated receptor 2 in allergic rhinitis. 54 61
17727088 2007
24
Asthma and rhinitis symptoms in individuals from different socioeconomic levels in a Brazilian city. 54 61
17619568 2007
25
Local IgE production and positive nasal provocation test in patients with persistent nonallergic rhinitis. 54 61
17337294 2007
26
What's new in paediatric sleep? 54 61
17419982 2007
27
Inverse relation between nasal fluid Clara Cell Protein 16 levels and symptoms and signs of rhinitis in allergen-challenged patients with intermittent allergic rhinitis. 54 61
17298427 2007
28
Applicability of extracellular electrical impedance tomography in monitoring respiratory tract inflammation. 54 61
17323861 2007
29
Subjects with non-allergic non-infectious perennial rhinitis do not show nasal hyper-responsiveness to bradykinin. 54 61
17043856 2007
30
Uteroglobin-related protein 1 and clara cell protein in induced sputum of patients with asthma and rhinitis. 54 61
17218572 2007
31
Eosinophil cationic protein, specific IgE and IgG4 in human toxocariasis. 54 61
17125552 2006
32
Management of asthma with anti-immunoglobulin E: a review of clinical trials of omalizumab. 54 61
16949266 2006
33
The role of allergic rhinitis in nasal responses to sudden temperature changes. 54 61
17088139 2006
34
[Is the seric eosinophil cationic protein level a valuable tool of diagnosis in clinical practice?]. 54 61
16647168 2006
35
Association between angiotensin-converting enzyme gene polymorphism and childhood allergic rhinitis in Taiwan. 54 61
16926975 2006
36
Atopy patch testing in children with asthma and rhinitis symptoms allergic to house dust mite. 54 61
16846452 2006
37
Intercellular adhesion molecule 1 and tumor necrosis factor alpha in asthma and persistent allergic rhinitis: relationship with disease severity. 54 61
16892784 2006
38
Determination of structure and transcriptional regulation of CYSLTR1 and an association study with asthma and rhinitis. 54 61
16771777 2006
39
Low prevalence of the intrinsic form of atopic dermatitis among adult patients. 54 61
16629795 2006
40
Allergen-induced interleukin-9 production in vitro: correlation with atopy in human adults and comparison with interleukin-5 and interleukin-13. 54 61
16433854 2006
41
Lack of association between the IL13 variant Arg110Gln and susceptibility to cedar pollinosis in a Japanese population. 54 61
16272823 2006
42
Sensitization to blackgram in patients with bronchial asthma and rhinitis: clinical evaluation and characterization of allergens. 54 61
16364164 2006
43
[Serum eosinophil cationic protein (ECP) in patients with perennial rhinitis and atopic dermatitis, allergic to house dust mites]. 54 61
16521419 2005
44
Efficacy of intramuscular BCG polysaccharide nucleotide on mild to moderate bronchial asthma accompanied with allergic rhinitis: a randomized, double blind, placebo-controlled study. 54 61
16232343 2005
45
Major lymphocyte populations and T-cell expression of ICAM-1 and L-selectin adhesion molecules in Kuwaitis with asthma and rhinitis. 54 61
17290844 2005
46
Double-blind comparative study of cluster and conventional immunotherapy schedules with Dermatophagoides pteronyssinus. 54 61
15990782 2005
47
Low levels of CC16 in nasal fluid of children with birch pollen-induced rhinitis. 54 61
15813809 2005
48
Immunological characterization of a recombinant tropomyosin from a new indoor source, Lepisma saccharina. 54 61
15836758 2005
49
Aspirin sensitivity: implications for patients with coronary artery disease. 54 61
15613671 2004
50
Long-term acquisition of allergen-specific IgE and asthma following allogeneic bone marrow transplantation from allergic donors. 54 61
15280196 2004

Variations for Rhinitis

Expression for Rhinitis

Search GEO for disease gene expression data for Rhinitis.

Pathways for Rhinitis

Pathways related to Rhinitis according to GeneCards Suite gene sharing:

(show all 35)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.93 VCAM1 RNASE3 POMC IL5 IL4R IL4
2
Show member pathways
13.64 NR3C1 NGF IL5 IL4R IL4 IL13
3
Show member pathways
13.49 NGF IL5 IL4R IL4 IL13 ICAM1
4
Show member pathways
13.37 NGF IL5 IL4R IL4 IL13 CXCL8
5
Show member pathways
13.23 NGF IL5 IL4R IL4 IL13 CXCL8
6
Show member pathways
13.22 VCAM1 POMC IL5 IL4R IL4 IL13
7 12.79 KNG1 IL5 IL4R IL4 IL13 CXCL8
8
Show member pathways
12.78 RNASE3 IL5 IL4 IL13 ICAM1 EPX
9
Show member pathways
12.32 IL4R IL4 IGHE HRH1 CCL11
10
Show member pathways
12.3 IL5 IL4R IL4 IL13
11
Show member pathways
12.29 ICAM1 CXCL8 CCL5 CCL11
12
Show member pathways
12.24 IL5 IL4 IL13 CXCL8 CCL11
13
Show member pathways
12.22 NGF IL5 IL4 IL13 CXCL8
14 12.14 NR3C1 NGF IL13 CXCL8
15 11.84 VCAM1 ICAM1 CXCL8
16 11.83 IL5 IL4R IL4
17 11.8 ICAM1 CXCL8 CCL5
18 11.73 IL5 IL4 IL13
19
Show member pathways
11.71 IL5 IL4 CXCL8
20 11.65 IL4 IL13 CCL5 CCL11
21 11.6 IL5 IL4R IL4 IGHE CCL11
22
Show member pathways
11.58 VCAM1 NR3C1 ICAM1 CXCL8
23 11.51 VCAM1 ICAM1 CXCL8
24 11.44 VCAM1 ICAM1 CXCL8
25 11.43 IL5 IL4 IL13 CXCL8 CCL5 CCL11
26 11.41 IL4 IL13 ICAM1 CXCL8 CCL5
27 11.41 POMC NR3C1 IL5 IL4 IL13 ICAM1
28 11.35 VCAM1 KNG1 ICAM1
29 11.33 VCAM1 POMC IL4R IL4 IL13 IGHE
30 11.32 IL5 IL4R IL4 IL13 CCL11
31 11.29 IL5 IL4R IL4
32 11.26 IL5 IL4 IL13
33 11.21 IL5 IL4 IL13
34 11.14 IL5 IL4 IL13
35 10.9 NGF IL5 IL4 IL13 CXCL8 CCL5

GO Terms for Rhinitis

Cellular components related to Rhinitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.77 RNASE3 POMC NGF KNG1 IL5 IL4R
2 extracellular space GO:0005615 9.47 VCAM1 RNASE3 POMC NGF KNG1 IL5

Biological processes related to Rhinitis according to GeneCards Suite gene sharing:

(show all 25)
# Name GO ID Score Top Affiliating Genes
1 G protein-coupled receptor signaling pathway GO:0007186 10.11 POMC KNG1 HRH1 CYSLTR1 CXCL8 CCL5
2 signal transduction GO:0007165 10.1 POMC NR3C1 IL5 IL4R IL4 HRH1
3 chemotaxis GO:0006935 9.83 CYSLTR1 CXCL8 CCL5 CCL11
4 cellular response to interferon-gamma GO:0071346 9.8 ICAM1 CCL5 CCL11
5 positive regulation of cold-induced thermogenesis GO:0120162 9.79 IL4R IL4 IL13
6 neutrophil chemotaxis GO:0030593 9.77 CXCL8 CCL5 CCL11
7 chemokine-mediated signaling pathway GO:0070098 9.76 CXCL8 CCL5 CCL11
8 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.75 IL4 IL13 CCL5
9 positive regulation of T cell proliferation GO:0042102 9.72 VCAM1 IL4 CCL5
10 inflammatory response GO:0006954 9.7 KNG1 IL5 IL13 HRH1 CXCL8 CCL5
11 positive regulation of B cell proliferation GO:0030890 9.67 IL5 IL4 IL13
12 negative regulation of endothelial cell apoptotic process GO:2000352 9.65 IL4 IL13 ICAM1
13 cellular response to tumor necrosis factor GO:0071356 9.65 VCAM1 ICAM1 CXCL8 CCL5 CCL11
14 cellular response to interleukin-1 GO:0071347 9.62 ICAM1 CXCL8 CCL5 CCL11
15 negative regulation of G protein-coupled receptor signaling pathway GO:0045744 9.61 CXCL8 CCL5
16 neutrophil activation GO:0042119 9.61 CXCL8 CCL5
17 leukocyte cell-cell adhesion GO:0007159 9.61 VCAM1 ICAM1 CCL5
18 positive regulation of mast cell degranulation GO:0043306 9.59 IL4R IL13
19 chronic inflammatory response GO:0002544 9.56 VCAM1 CCL11
20 immune response GO:0006955 9.56 IL5 IL4R IL4 IL13 IGHE CXCL8
21 positive regulation of immunoglobulin production GO:0002639 9.54 IL4R IL13
22 eosinophil chemotaxis GO:0048245 9.54 HRH1 CCL5 CCL11
23 membrane to membrane docking GO:0022614 9.51 VCAM1 ICAM1
24 negative regulation of complement-dependent cytotoxicity GO:1903660 9.46 IL4 IL13
25 cytokine-mediated signaling pathway GO:0019221 9.36 VCAM1 POMC IL5 IL4R IL4 IL13

Molecular functions related to Rhinitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 chemokine activity GO:0008009 9.13 CXCL8 CCL5 CCL11
2 cytokine activity GO:0005125 9.1 IL5 IL4 IL13 CXCL8 CCL5 CCL11

Sources for Rhinitis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....